DRUG · Mapped RxNorm record
omalizumab
Normalized identity: omalizumabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.
NCT00500539
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedOpen Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Asthmaverified · MONDO: asthma
Interventions
omalizumabDRUG · verified · RxNorm: omalizumab
Sponsors & collaborators
Mapped research locations
HoustonTexas, United States2Buenos AiresArgentina2PhiladelphiaPennsylvania, United States1St LouisMissouri, United States1San DiegoCalifornia, United States1ColumbusOhio, United States1MinneapolisMinnesota, United States1ProvidenceRhode Island, United States1ScottsdaleArizona, United States1Fort WorthTexas, United States1ToledoOhio, United States1Overland ParkKansas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00500539 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.